Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Pioglitazone has been shown to reduce fasting triglyceride levels. The mechanisms of this effect have not been fully elucidated, but decreased lipolysis may contribute to blunt the hypertriglyceridemic response to a meal. To test this hypothesis, we studied 27 type 2 diabetes mellitus (T2DM) patients and 7 sex-, age-, and body mass index-matched nondiabetic controls. Patients were randomized to pioglitazone (45 mg/day) or placebo for 16 wk. Whole body lipolysis was measured [as the [2 H 5]glycerol rate of appearance (R a)] in the fasting state and for 6 h following a mixed meal. Compared with controls, T2DM had higher postprandial profiles of plasma triglycerides, free fatty acid (FFA), and β-hydroxybutyrate, and a decreased suppression of glycerol R a( P < 0.04) despite higher insulin levels [268 (156) vs. 190 (123) pmol/l, median (interquartile range)]. Following pioglitazone, triglycerides and FFA were reduced ( P = 0.05 and P < 0.04, respectively), and glycerol R a was more suppressed [−40 (137) vs. +7 (202) μmol/min of placebo, P < 0.05] despite a greater fall in insulin [−85 (176) vs. −20 (58) pmol/l, P = 0.05]. We conclude that, in well-controlled T2DM patients, whole body lipolysis is insulin resistant, and pioglitazone improves the insulin sensitivity of lipolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge, D. J. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00715.x · Cited by 91
Basu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., & Rizza, R. A. (2008) · Diabetes · doi:10.2337/db07-0827 · Cited by 63
Research works printed but not linked: 23
- 10.1007/s00125-005-0092-4 · DOI
- 10.2337/dc06-2558 · DOI · Paper page
- 10.2337/diacare.27.7.1660 · DOI · Paper page
- 10.1007/s00125-006-0560-5 · DOI
- 10.1172/JCI116544 · DOI · Paper page
- 10.2337/diab.36.11.1341 · DOI · Paper page
- 10.1038/sj.clpt.6100034 · DOI · Paper page
- 10.1152/jappl.1999.87.5.1813 · DOI · Paper page
- 10.1038/nm780 · DOI · Paper page
- 10.1152/ajpendo.1999.276.5.E863 · DOI · Paper page
- 10.2337/diabetes.49.5.677 · DOI · Paper page
- 10.1210/jcem.86.11.8027 · doi:10.1210/jcem.86.11.8027 · Paper page
- 10.1152/ajpendo.00662.2006 · DOI
- 10.2337/diabetes.50.5.1158 · DOI · Paper page
- 10.1161/ATVBAHA.107.150193 · DOI · Paper page
- Swislocki AL, Chen YD, Golay A, Chang MO, Reaven GM.Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes.Diabetologia30: 622–626, 1987. · DOI
- 10.1038/nm0703-811 · DOI
- 10.1007/s00125-004-1619-9 · DOI
- 10.1016/S0026-0495(03)00106-9 · DOI
- 10.2337/diacare.28.4.844 · DOI · Paper page
- 10.1210/jc.2005-1073 · DOI
- 10.2337/diabetes.54.9.2720 · DOI · Paper page
- Wolfe R.Radioactive and Stable Isotope Tracers in Biomedicine. New York: Wiley-Liss, 1992. · DOI
Cited by
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Self-citationAzzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.054 · Cited by 369
Gastaldelli, A., Gaggini, M., & DeFronzo, R. A. (2017) · Diabetes · doi:10.2337/db16-1167 · Cited by 344
“By using tracers, it is possible to quantitate palmitate turnover (17,18) and the rate of glycerol release (19,20) to provide an index of lipolysis.”
Self-citationImpact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Self-citationLipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“82 At the same time, all PPAR-c agonists have a general insulin-sensitising effect by improving adipose tissue insulin sensitivity, 80,85 promoting the suppression of peripheral lipolysis, 86 and thus decreasing the concentrations of plasma fatty acids and their ef fl ux to the liver.”
Self-citation
Metadata
- Authors
- Gastaldelli, A., Casolaro, A., Ciociaro, D., Frascerra, S., Nannipieri, M., Buzzigoli, E., & Ferrannini, E.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2009-07
- Volume
- 297
- Issue
- 1
- Pages
- E225-E230
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2100806174
- Cited by
- 36
- References
- 9
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. https://app.cochat.ai/papers/10.1152/ajpendo.90960.2008
- The paper
- Gastaldelli, A., Casolaro, A., Ciociaro, D., Frascerra, S., Nannipieri, M., Buzzigoli, E., & Ferrannini, E. (2009). Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.90960.2008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.